Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Mereo BioPharma entered an option and license agreement with Sentynl Therapeutics for the U.S. commercialization rights to alvelestat, a Phase 3-ready oral treatment for AATD-LD. Under the deal, Mereo receives a non-refundable option fee and, upon exercise, is eligible for $40 million in upfront and R&D payments, up to $435 million in milestones, and double-digit royalties on U.S. sales.
Key figures
- Drug Name
- alvelestat
- Phase Of Trial
- Phase 3
- Potential milestones
- $435 million
- Patient prevalence us
- 50,000-80,000
- Upfront and rnd payments
- $40 million
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.